Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: December 12th 2022 | Updated: November 13th 2024
When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis
Published: June 17th 2024 | Updated: November 13th 2024
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
Published: January 23rd 2024 | Updated: November 13th 2024
Peers Discuss Impressions of Tivozanib’s Role as Third-Line RCC Therapy
Published: July 18th 2023 | Updated: November 13th 2024
Tara Graff: ‘My Heart Has Always Been in Research’
Published: January 11th 2023 | Updated: November 13th 2024
IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCC